Supporting Information

for

Efficient chemoenzymatic synthesis of sialyl Tn-antigens and derivatives[†]

Li Ding,^{ab} Hai Yu,^b Kam Lau,^b Yanhong Li,^b Saddam Muthana,^{bc} Junru Wang^a and Xi Chen*^b

^aCollege of Science, Northwest A&F University, Yangling, Shaanxi, China ^bDepartment of Chemistry, University of California, One Shields Avenue, Davis, California 95616, USA. E-mail: chen@chem.ucdavis.edu.edu; Fax: +1 530-752-8995; Tel: +1 530-754-6037 ^cCurrent address: National Cancer Institute, Frederick, Maryland, 21702, USA.

*Correspondence to: Xi Chen, Department of Chemistry, University of California, One Shields Avenue, Davis, California, 95616, USA. Tel: 530-754-6037; Fax: 530-752-8995; E-mail: chen@chem.ucdavis.edu

Table of Contents

Table S1. Apparent kinetic parameters of Psp2,6ST(15–501)-His6 and His6-Pd2,6ST(16–497)	S2
Figure S1. SDS PAGE of Psp2,6ST(15–501)-His ₆ and His ₆ -Pd2,6ST(16–497)	S2
Figure S2. Effects of Mg ²⁺ , Mn ²⁺ , EDTA, and DTT on the activity of Psp2,6ST(15–501)-His ₆	S2
Figure S3. pH Profiles of Psp2,6ST(15–501)-His ₆ and His ₆ -Pd2,6ST(16–497)	S3
Bacterial strains, plasmids, and materials	S3
Cloning, expression, and purification of Psp2,6ST(15–501)-His ₆	S3–S4
SDS-PAGE analysis of Psp2,6ST(15–501)-His ₆	S4
Effects of metal ions, DTT and EDTA	S4–S5
pH profile study for Psp2,6ST(15–501)-His ₆ and His ₆ -Pd2,6ST(16–497)	S5
Kinetics assay	S5–S6
One-pot three-enzyme preparative-scale synthesis of STn and its derivates	S6–S9
References	S9
¹ H and ¹³ C NMR spectra for compounds 14–25	S10–S21

Enzymes	Psp2,6ST(15–501)-His ₆			His ₆ -Pd2,6ST(16–497)		
Substrates	$K_{\rm m}({\rm mM})$	$k_{\text{cat}} (\min^{-1})$	$k_{\rm cat}/K_{ m m}$	$K_{\rm m}({\rm mM})$	$k_{\text{cat}} (\min^{-1})$	$k_{\rm cat}/K_{ m m}$
			$(mM^{-1} min^{-1})$			$(mM^{-1} min^{-1})$
CMP-Neu5Ac	0.62 ± 0.04	$(1.4\pm0.1)\times10^2$	2.2×10^2	0.90±0.20	$(1.6\pm0.1)\times10^2$	1.7×10^2
LacβMU	0.36±0.07	$(1.0\pm0.1)\times10^2$	2.9×10^2	^a 0.80±0.10	$^{a}(1.4\pm0.1)\times10^{2}$	$a1.8 \times 10^{2}$
CMP-Neu5Ac	3.9±0.4	4.8±0.2	1.2	11±1	0.38±0.01	0.034
GalNAca2AA	9.5±2.7	31±5	3.3	51±5	4.7±0.2	0.09
GalNAcaOSer	1.4±0.1	34±3	24	1.6±0.2	24±1	15
GalNAcaOThr	5.9±1.6	16±1	2.7	10±1	8.3±0.2	0.8

Table S1. Apparent kinetic parameters of Psp2,6ST(15–501)-His₆ and His₆-Pd2,6ST(16–497).

^aData were cited from a paper reported previously.¹



Figure S1. SDS-PAGE of A, Psp2,6ST(15–501)-His₆ and B, MBP-Psp2,6ST(15–501)-His₆. Lanes: 1, whole cell extraction before induction; 2, whole cell extraction after induction; 3, cell lysate after induction; 4, Ni²⁺-column purified protein; 5, protein standards.



Figure S2. Effects of metal ions (Mg^{2+} and Mn^{2+}), EDTA, and DTT on the sialyltransferase activity of Psp2,6ST(15–501)-His₆ by quantitative HPLC analysis. White columns, CMP-Neu5Ac and Lac β MU were used as substrates; black columns, CMP-Neu5Ac and GalNAc α 2AA were used as substrates. Reaction conditions were the same as those for pH profiles.



Figure S3. The pH profiles of A, Psp2,6ST(15–501)-His₆ and B, His₆-Pd2,6ST(16–497) when Lac β MU (**•**), GalNAc α 2AA (**•**), or GalNAc α Ser (**•**) was used as the sialyltransferase acceptor. 100% conversion was defined as the formation of 1 mM product (Neu5Ac α 2–6Lac β MU or Neu5Ac α 2–6GalNAc α 2AA or Neu5Ac α 2–6GalNAc α Ser). Activities were measured in duplicate at indicated pH at 20 °C for 20 min. Buffers (200 mM) used were: NaOAc-HOAc, pH 4.0–4.5; MES, pH 5.0–6.0; HEPES, pH 7.0; Tris-HCl, pH 7.5–9.0; and CAPS, pH 10.0–11.0. Amounts of enzymes used: 0.3 μ M for Psp2,6ST(15–501)-His₆ when Lac β MU was used as the acceptor; 6 μ M for Psp2,6ST(15–501)-His₆ and 30 μ M for His₆-Pd2,6ST(16–497) when GalNAc α 2AA was used as the acceptor substrate; 0.6 μ M for both Psp2,6ST(15–501)-His₆ and His₆-Pd2,6ST(16–497) when GalNAc α Ser was used as the acceptor substrate.

Bacterial strains, plasmids, and materials.

Primers, *Escherichia coli* DH5 α electrocompetent cells and BL21 (DE3) chemically competent cells were from Invitrogen (Carlsbad, CA). Full-length synthetic gene of *Photobacterium sp.* JT-ISH-224 α 2–6-sialyltransferase with codons optimized for *E. coli* expression system was custom-synthesized by Geneart AG (Regensburg, Germany). Vector plasmids pET15b and pET22b (+) were from Novagen (EMD Biosciences Inc., Madison, WI). Ni²⁺-NTA agarose (nickel-nitrilotriacetic acid agarose), QIAprep spin miniprep kit, and QIAEX II gel extraction kit were from Qiagen (Valencia, CA). Herculase enhanced DNA polymerase was from Stratagene (La Jolla, CA). T4 DNA ligase, 1 kb DNA ladder, vector plasmid pMAL-c4X, restriction enzymes BamHI, XhoI, NdeI and SaII were from New England Biolabs Inc. (Beverly, MA). Precision Plus Protein Standards were from Bio-Rad (Hercules, CA). Bicinchoninic acid (BCA) protein assay kit was from Pierce Biotechnology Inc. (Rockford, IL). Ni²⁺-NTA agarose (nickel-nitrilotriacetic acid agarose) was from 5 PRIME (Gaithersburg, MD).

Cloning, expression, and purification of Psp2,6ST(15-501)-His₆

Psp2,6ST was cloned into pET22b(+) and pMal-c4x vectors and expressed in E. coli BL21 (DE3) cells as C-His₆-tagged fusion proteins with or without additional N-MBP-tag. The primers used to clone Psp2,6ST(15–501)-His₆ pET22b(+) vector were: forward primer 5'in GATCCATATGTGTAATAATAGCGAAGAAAATAC-3' (NdeI restriction site is underlined), reverse primer 5'-CCGCTCGAGTGCCCAAAACAGGACGTTTT-3' (XhoI restriction site is underlined). The primers used to clone MBP-Psp2.6ST(15-501)-His₆ fusion protein were: forward primer is same as the Psp2,6ST(15–501)-His₆ fusion protein, reverse one used in cloning primer 5'-ACGCGTCGACTTAGTGGTGGTGGTGGTGGTGGTGGTGGTGCCCAA-3' (Sall restriction site is underlined, codons encoding hexa-histidine are in italics). PCRs for amplifying the target gene were performed in a 50 μ L reaction mixture containing template DNA (1 μ g), forward and reverse primers (1 μ M each), 10 \times Herculase buffer (5 µL), dNTP mixture (1 mM), and 5 U (1 µL) of Herculase-enhanced DNA polymerase. The reaction mixture was subjected to 29 cycles of amplification with an annealing

temperature of 52 °C. The resulting PCR product was purified and digested with restriction enzymes. The purified and digested PCR product was ligated with predigested vectors and transformed into *E. coli* DH5 α electrocompetent cells. Selected clones were grown for minipreps and characterization by restriction mapping and DNA sequencing performed by Davis Sequencing Facility in the University of California-Davis.

Positive plasmid was selected and transformed into BL21 (DE3) chemically competent cells. The plasmid-bearing *E. coli* strain was cultured in LB-rich medium (10 g/L tryptone, 5 g/L yeast extract, and 10 g/L NaCl) supplemented with ampicillin (100 μ g/mL). Overexpression of the target protein was achieved by inducing the *E. coli* culture with 0.3 mM of isopropyl-1-thio- β -D-galactopyranoside (IPTG) when the OD_{600nm} of the culture reaches 0.8–1.0 and incubating at 20 °C for 20 h with vigorous shaking at 250 rpm in a C25KC incubator shaker (New Brunswick Scientific, Edison, NJ).

Target proteins were purified from cell lysate. To obtain the cell lysate, cell pellet harvested by centrifugation at 4000 rpm for 2 h was resuspended in lysis buffer (pH 7.5, 100 mM Tris-HCl containing 0.1% Triton X-100) (20 mL/L cell culture). Lysozyme (50 μ g/mL) and DNaseI (3 μ g/mL) were then added and the mixture was incubated at 37 °C for 1 hour with vigorous shaking. Cell lysate was obtained by centrifugation at 11,000 rpm for 30 min as the supernatant. Purification of His-tagged proteins from the lysate was achieved using an AKTA FPLC system (GE Healthcare) equipped with a HisTrapTM FF 5 mL column. The column was pre-equilibrated with 10 column volumes of binding buffer (5 mM imidazole, 0.5M NaCl, 50 mM Tris-HCl, pH 7.5) before the lysate was loaded. Followed by washing with eight column volumes of binding buffer, 10 column volumes of washing buffer (50 mM imidazole, 0.5 M NaCl, 50 mM Tris-HCl, pH 7.5), the protein was eluted with a linear gradient of elute buffer containing 50–250 mM imidazole in Tris-HCl buffer (50 mM, pH 7.5, 0.5 M NaCl). The fractions containing the purified enzymes were collected and stored at 4 °C.

Protein concentration was determined in a 96-well plate using bicinchoninic acid with BSA as standard. The absorbance was measured at 562 nm using a plate reader.

SDS-PAGE analysis of Psp2,6ST(15–501)-His₆

SDS-PAGE analysis (Figure S1, A) shows both the recombinant proteins in pET system and pMal-c4x system can be well expressed with molecular weight of about 56 kDa and 99.5 kDa respectively, which are close to 55 kDa calculated for the Psp2,6ST(15-501)-His₆ and 98 kDa calculate for the MBP-Psp2,6ST(15-501)-His₆. The SDS-PAGE analysis of Psp26ST(15-501)-His₆ in pET22b (+) system (Figure S1A) indicates that it can be expressed in a large amount which consists of about 80% of the total protein extracts from *E. coli* host cells. But the soluble portion of the target protein that can be observed in the lysate is not high. So pMal-c4x expression system was tested to improve the protein solubility. However, SDS-PAGE analysis of MBP-Psp2,6ST(15-501)-His₆ expression (Figure S1B) showed that the pMal-c4x expression system did not improve the expression level.

Effects of metal ions, DTT and EDTA

EDTA (5 mM, 10 mM), different concentrations (5, 10, 20, 50 mM) of MgCl₂ or MnCl₂, and various concentrations of DTT (0.2, 1, 5, 10 mM) were used in a Tris-HCl buffer (pH 8.0, 200 mM) or MES buffer (pH 5.0, 200 mM) to analyze their effects on the α 2–6-sialyltransferase activity of Psp2,6ST(15–501)-His₆ for acceptor Lac β MU or GalNAc α 2AA. Other components used in the reaction system are the same as used in the pH profile. Reaction without EDTA, DTT, and metal ions was used as a control. The effects of metal ions Mg²⁺ and Mn²⁺ as well as DTT and the chelating agent EDTA on the α 2–6-

The effects of metal ions Mg²⁺ and Mn²⁺ as well as DTT and the chelating agent EDTA on the $\alpha 2$ -6sialyltransferase activity of Psp2,6ST(15–501)-His₆ toward Lac β MU and GalNAc $\alpha 2$ AA were examined at pH 5.0 and 8.0 respectively. The results (Figure S2) indicate that a divalent metal ion is required as the enzyme activity decreased dramatically when EDTA is applied at 5 mM and Lac β MU is used as acceptor. However the addition of Mg²⁺ up to 50 mM does not affect the sialyltransferase activity of the enzyme, but the activity drops a little when Mn²⁺ ion is used in the reaction system. DTT up to 10 mM does not significantly increase the activity of the enzyme for both acceptor Lac β MU and GalNAc α 2AA, indicating disulfide formation is not required for the sialyltransferase activity of Psp2,6ST(15–501)-His₆.

pH profile study for Psp2,6ST(15–501)-His₆ and His₆-Pd2,6ST(16–497)

Typical enzymatic assays were performed in a total volume of 10 µL in a buffer (200 mM) with pH varying from 4.0 to 11.0. The buffers used were: NaOAc-HOAc, pH 4.0-4.5; MES, pH 5.0-6.0; HEPES, pH 7.0; Tris-HCl, pH 7.5-9.0; and CAPS, pH 10.0-11.0. Reaction system for acceptor LacBMU is: CMP-Neu5Ac (1 mM), LacBMU (1 mM), and the recombinant Psp2,6ST(15–501)-His₆ (0.3 µM). Reaction system for acceptor GalNAca2AA is: CMP-Neu5Ac (4 mM), GalNAca2AA (1 mM), and the recombinant enzyme Psp2,6ST(15–501)-His₆ (6 μ M) or His₆-Pd2,6ST(16–497) (30 μ M). Reaction system for acceptor GalNAc α Ser is: CMP-Neu5Ac (1 mM), GalNAc α Ser (1 mM), and the recombinant enzyme Psp2,6ST(15-501)-His₆ or His₆-Pd2,6ST(16-497) (0.6 µM). All reactions were allowed to proceed for 20 min at 20 °C. The reaction mixture was guenched by adding ice cold 25% (v/v) acetonitrile to make 100-fold dilution for LacBMU, 500-fold dilution for GalNAcaSer, or quenched by adding ice cold acetonitrile 30% (v/v) (for GalNAc α 2AA) to make 80-fold dilution. The samples were then kept on ice until aliquots of 5 µL were injected and analyzed by a Shimadzu LC-2010A system equipped with a membrane on-line degasser, a temperature control unit, and a fluorescence detector. A reverse-phase Premier C18 column (250×4.6 mm i.d., 5 µm particle size, Shimadzu) protected with a C18 guard column cartridge was used. The mobile phase was 25% (v/v) acetonitrile (for Lac β MU and GalNAc α Ser) or 30% (v/v) acetonitrile (for GalNAc α 2AA). The fluorescent-labeled Lac β MU and Neu5Ac α 2–6Lac β MU were detected by excitation at 325 nm and emission at 372 nm. The fluorescent-labeled GalNAc α 2AA and Neu5Ac α 2–6GalNAc α 2AA were detected by excitation at 315 nm and emission at 400 nm. The fluorescent-labeled GalNAcaSer and Neu5Aca2-6GalNAcaSer were detected by excitation at 313 nm and emission at 262 nm. All assays were carried out in duplicate.

Kinetics assay

Enzymatic assays for Psp2,6ST(15–501)-His₆ were carried out at 20 °C for 20 minutes in a total volume of 10 μ L in a proper buffer at the optimal pH according to the pH profile. Specific conditions for Psp2,6ST(15–501)-His₆ when Lac β MU was used as an acceptor: Tris-HCl buffer (200 mM, pH 8.0), enzyme (0.3 μ M), varied concentrations of Lac β MU (0.1, 0.25, 0.4, 1, 2, 4, and 6 mM) with a fixed concentration of CMP-Neu5Ac (1 mM) or varied concentrations of CMP-Neu5Ac (0.1, 0.25, 0.4, 1, 2, 4, and 6 mM) with a fixed concentration of Lac β MU (1 mM). Specific conditions for Psp2,6ST(15–501)-His₆ when GalNAca2AA was used as an acceptor: MES buffer (200 mM, pH 5.0), enzyme (6 μ M), varied concentrations of GalNAca2AA (0.5, 0.8, 1, 2, 4, 8, and 10 mM) and a fixed concentration of CMP-Neu5Ac (4 mM) or varied concentrations of CMP-Neu5Ac (0.5, 1, 2, 4, 5, 8, and 10 mM) with a fixed concentration of GalNAca2AA (1 mM). Specific conditions for His₆-Pd2,6ST(16–497) when GalNAca2AA (0.5, 1, 2, 4, 10, 20, 40, 80, and 100 mM) with a fixed concentration of CMP-Neu5Ac (4 mM) or varied concentrations of CMP-Neu5Ac (0.5, 1, 2, 4, 10, 20, 40, 80, and 100 mM) with a fixed concentration of MM) with a fixed concentration of CMP-Neu5Ac (4 mM) or varied concentrations of CMP-Neu5Ac (0.5, 1, 2, 4, 10, 20, 40, 80, and 100 mM) with a fixed concentration of MM) with a fixed concentration of CMP-Neu5Ac (4 mM) or varied concentrations of CMP-Neu5Ac (0.5, 1, 2, 4, 10, 20, 40, 80, and 100 mM) with a fixed concentration of CMP-Neu5Ac (4 mM) or varied concentrations of CMP-Neu5Ac (0.5, 1, 2, 4, 10, 20, 40, 80, and 100 mM) with a fixed concentration of MM) with a fixed concentration of GalNAca2AA (1 mM). Specific conditions for Psp2,6ST(15–501)-

His₆ and His₆-Pd2,6ST(16–497) when GalNAc α Ser was used as an acceptor: Tris-HCl buffer (200 mM, pH 8.0), varied concentrations of GalNAc α Ser (0.1, 0.25, 0.5, 1, 2, 4, 8, and 10 mM), a fixed concentration of CMP-Neu5Ac (2 mM), and Psp2,6ST(15–501)-His₆ (0.6 μ M) or His₆-Pd2,6ST(16–497) (2.0 μ M). Specific conditions for Psp2,6ST(15–501)-His₆ and His₆-Pd2,6ST(16–497) when GalNAc α Thr was used as an acceptor: Tris-HCl buffer (200 mM, pH 8.0), varied concentrations of GalNAc α Thr (0.5, 1, 2, 4, 10, 20, 40, 60 mM), a fixed concentration of CMP-Neu5Ac (4 mM), and Psp2,6ST(15–501)-His₆ (2.0 μ M) or His₆-Pd2,6ST(16–497) (10.0 μ M).

General methods

Chemicals were purchased and used without further purification. ¹H NMR (600 MHz) and ¹³C NMR (150 MHz) spectra were recorded on a Varian VNMRS 600 MHz spectrometer. High resolution electrospray ionization (ESI) mass spectra were obtained at the Mass Spectrometry Facility in the University of California, Davis. Optical rotation was recorded on an Autopol IV Automatic polarimeter at 589 nm wavelength. Infrared spectra were recorded on a PerkinElmer Spectrum 100 ATR-FTIR. Silica gel 60 Å was used for flash column chromatography. Thin-layer chromatography (TLC) was performed on silica gel plates using *p*-anisaldehyde sugar stain or 5% sulfuric acid in ethanol stain for detection. Gel filtration chromatography was performed using a column (100 cm \times 2.5 cm) packed with BioGel P-2 Fine resins. Sodium pyruvate, ManNAc (1), and mannose (3) and were purchased from Sigma. Lac β MU, GalNAc derivatives 10–13, ManNAc derivatives 2, 4–9 were synthesized as described previously.^{2–5}

One-pot three-enzyme preparative-scale synthesis of STn and its derivates

α-GalNAc glycosides (**10–13**, 41–55 mg), a sialic acid precursor (**1–9**, 1.5 equiv.), sodium pyruvate (5.0 equiv.), and CTP (1.5 equiv.) were dissolved in Tris-HCl buffer (10 mL, 100 mM, pH 8.5) containing MgCl₂ (20 mM) and appropriate amounts of Pm aldolase (1.5 mg), NmCSS (1.0 mg), and Psp2,6ST(15–501)-His₆ (2.5–3.0 mg). The pH condition of the mixture was controlled at 8.0 for acceptor **12** or **13** to avoid the loss of Fmoc group, and at 7.5 for donor **5** to avoid the loss of *O*-acetyl. All other reactions were carried out at pH 8.5. All reactions were incubated in an incubator shaker at room temperature for around 2 days with agitation at 140 rpm. The product formation was monitored by TLC developed with EtOAc:MeOH:H₂O:HOAc = 4:2:1:0.1 (by volume) and stained with *p*-anisaldehyde sugar stain. When an optimal yield was achieved, the reaction was stopped by adding the same volume of cold EtOH and kept at 4 °C for 30 min. The mixture was then centrifuged and the precipitates were removed. The supernatant was concentrated, passed through a BioGel P-2 gel filtration column, and eluted with water to obtain partially purified product. A silica gel column was then used to obtain the final pure sialylated products using EtOAc:MeOH:H₂O = 6:2:1 (by volume) as the mobile phase.

3-Azidopropyl *O*-(5-acetamido-3,5-dideoxy-D-*glycero*- α -D-*galacto*-2-nonulopyranosylonic acid)-(2 \rightarrow 6)-2-acetamido-2-deoxy- α -D-galactopyranoside (14, Neu5Ac α 2–6GalNAc α ProN₃). 69 mg, Yield, 76%; white foam. [α]_D²³ = +55.0° (*c* 1.0, H₂O); v_{max}/cm⁻¹ 3296 (s, OH), 2932 (s, C–H, alkene), 2100 (s, N₃), 1613 (s, C=O, carboxylic acid), 1560 (m, C=O, amide), 1031 (s, C-N); ¹H NMR (600 MHz, D₂O) δ 4.87 (d, 1H, *J* = 3.6 Hz), 4.12 (dd, 1H, *J* = 3.6 and 10.8 Hz), 4.03–3.75 (m, 8H), 3.70–3.39 (m, 8H), 2.72 (dd, 1H, *J* = 4.8 and 12.0 Hz, H-3_{eq}"), 2.03 (s, 2CH₃), 1.90 (m, 2H), 1.67 (t, 1H, *J* = 12.0 Hz, H-3_{ax}"); ¹³C NMR (75 MHz, D₂O) δ 175.17, 174.67, 173.55, 100.50, 97.21, 72.71, 71.92, 69.63, 68.68, 68.39, 68.38, 67.63, 65.30, 63.98, 62.77, 52.01, 50.09, 48.31, 40.42, 28.07, 22.20, 22.11. HRMS (ESI) *m/z* calcd for C₂₂H₃₈N₅O₁₄ (M+H) 596.2415, found 596.2408. **3-Azidopropyl** *O*-(5-glycolylamido-3,5-dideoxy-D-glycero- α -D-galacto-2-nonulopyranosylonic acid)-(2 \rightarrow 6)-2-acetamido-2-deoxy- α -D-galactopyranoside (15, Neu5Gc α 2–6GalNAc α ProN₃). 70 mg, Yield, 75%; white foam. [α]_D²³ = +58.7° (*c* 1.0, H₂O); v_{max}/cm⁻¹ 3290 (s, OH), 2932 (s, C–H, alkene), 2100 (s, N₃), 1611 (s, C=O, carboxylic acid), 1545 (m, C=O, amide), 1032 (s, C-N); ¹H NMR (600 MHz, D₂O) δ 4.72 (d, 1H, *J* = 3.6 Hz), 3.98 (dd, 1H, *J* = 3.6 and 11.4 Hz), 3.96 (s, 2H), 3.89 (dd, 1H, *J* = 3.6 and 7.8 Hz), 3.84 (d, 1H, *J* = 3.6 Hz), 3.78–3.59 (m, 8H), 3.50–3.25 (m, 6H), 2.58 (dd, 1H, *J* = 4.8 and 12.0 Hz, H-3_{eq}"), 1.88 –s, CH₃), 1.75 (m, 2H), 1.54 (t, 1H, *J* = 12.0 Hz, H-3_{ax}"); ¹³C NMR (75 MHz, D₂O) δ 175.92, 174.67, 173.57, 100.51, 97.21, 72.43, 71.96, 69.64, 68.67, 68.32, 68.12, 67.63, 65.29, 64.00, 62.73, 61.11, 51.69, 50.09, 48.30, 40.46, 28.06, 22.09. HRMS (ESI) *m/z* calcd for C₂₂H₃₈N₅O₁₅ (M+H) 612.2364, found 612.2356.

3-Azidopropyl *O*-(3-deoxy-D-glycero- α -D-galacto-2-nonulopyranosylonic acid)-(2 \rightarrow 6)-2-acetamido-2-deoxy- α -D-galactopyranoside (16, Kdn α 2–6GalNAc α ProN₃). 50 mg, Yield, 60%; white foam. [α]_D²⁴ = +52.1° (*c* 1.0, H₂O); v_{max}/cm⁻¹ 3271 (s, OH), 2927 (s, C–H, alkene), 2099 (s, N₃), 1603 (s, C=O, carboxylic acid), 1545 (m, C=O, amide), 1026 (s, C-N); ¹H NMR (600 MHz, D₂O) δ 4.86 (d, 1H, *J* = 3.6 Hz), 4.12 (dd, 1H, *J* = 3.6 and 10.8 Hz), 4.02 (dd, 1H, *J* = 3.6 and 8.4 Hz), 3.97 (d, 1H, *J* = 2.4 Hz), 3.91–3.40 (m, 14H), 2.66 (dd, 1H, *J* = 4.8 and 12.6 Hz, H-3_{eq}"), 2.03 (s, CH₃), 1.89 (m, 2H), 1.62 (t, 1H, *J* = 12.6 Hz, H-3_{ax}"); ¹³C NMR (75 MHz, D₂O) δ 174.67, 173.74, 100.47, 97.20, 73.70, 72.24, 70.30, 70.06, 69.67, 68.70, 68.06, 67.63, 65.29, 64.06, 62.83, 50.09, 48.30, 40.04, 28.06, 22.09. HRMS (ESI) *m*/z calcd for C₂₀H₃₅N₄O₁₄ (M+H) 555.2150, found 555.2141.

3-Azidopropyl 0-(5-methoxyacetamido-3,5-dideoxy-D-glycero- α -D-galacto-2 **nonulopyranosylonic acid**)-(2 \rightarrow 6)-2-acetamido-2-deoxy- α -D-galactopyranoside (17, **Neu5GcMea2-6GalNAcaProN3).** 82 mg, Yield, 86%; white foam. $[\alpha]_D^{24} = +58.1^{\circ}$ (*c* 1.0, H₂O); v_{max}/cm^{-1} 3296 (s, OH), 2937 (s, C–H, alkene), 2096 (s, N3), 1608 (s, C=O, carboxylic acid), 1545 (m, C=O, amide), 1029 (s, C-N); ¹H NMR (600 MHz, D₂O) δ 4.88(d, 1H, *J* = 3.6 Hz), 4.13 (dd, 1H, *J* = 3.6 and 10.8 Hz), 3.99 (s, 2H), 3.91–3.42 (m, 16H), 3.42 (s, 3H), 2.73 (dd, 1H, J=4.8, 12.6), 2.04(s, 3H), 1.90 (m, 2H), 1.69 (t, 1H, *J* = 12.6); ¹³C NMR (75 MHz, D₂O) δ 174.67, 173.60, 171.30, 100.52, 97.21, 72.41, 71.99, 71.01, 69.64, 68.68, 68.40, 68.13, 67.63, 65.30, 64.00, 62.74, 59.13, 51.67, 50.09, 48.31, 40.52, 28.07, 22.09. HRMS (ESI) *m/z* calcd for C₂₃H₄₀N₅O₁₅ (M+H) 626.2521, found 626.2514.

3-Azidopropyl *O*-(5-acetoxyacetamido-3,5-dideoxy-D-glycero-α-D-galacto-2nonulopyranosylonic acid)-(2→6)-2-acetamido-2-deoxy-α-D-galactopyranoside (18, Neu5GcAcα2–6GalNAcαProN₃). 67 mg, Yield, 68%; white foam. $[\alpha]_D^{24} = +48.2^{\circ}$ (*c* 1.0, H₂O); v_{max} /cm⁻¹ 3292 (s, OH), 2932 (s, C–H, alkene), 2099 (s, N₃), 1613 (s, C=O, carboxylic acid), 1542 (m, C=O, amide), 1028 (s, C-N); ¹H NMR (600 MHz, D₂O) δ 4.89 (d, 1H, *J* = 3.6 Hz), 4.14 (s, 2H), 4.17–3.46 (m, 14H), 2.77 (dd, 1H, *J* = 4.8 and 12.6 Hz), 2.06 (s, 3H), 1.93 (m, 2H), 1.72 (t, 1H, *J* = 12.6 Hz); ¹³C NMR (75 MHz, D₂O) δ 175.92, 174.67, 173.56, 171.00, 100.52, 97.21, 72.43, 71.96, 69.64, 68.68, 68.33, 68.12, 67.64, 65.31, 64.01, 62.74, 61.12, 59.47, 51.70, 50.09, 48.31, 40.46, 28.07, 22.10. HRMS (ESI) *m*/*z* calcd for C₂₄H₃₉N₅O₁₆ (M+H) 653.2392, found 653.2413.

3-Azidopropyl *O*-(5-azidoacetamido-3,5-dideoxy-D-*glycero*-α-D-*galacto*-2-nonulopyranosylonic acid)-(2→6)-2-acetamido-2-deoxy-α-D-galactopyranoside (19, Neu5AcN₃α2–6GalNAcαProN₃). 73

mg, Yield, 75%; white foam. $[\alpha]_D^{23} = +62.3^{\circ}$ (*c* 1.0, H₂O); v_{max}/cm^{-1} 3306 (s, OH), 2927 (s, C–H, alkene), 2106 (s, N₃), 1608 (s, C=O, carboxylic acid), 1547 (m, C=O, amide), 1032 (s, C-N); ¹H NMR (600 MHz, D₂O) δ 4.87 (d, 1H, *J* = 3.6 Hz), 4.13 (dd, 1H, *J* = 3.6 and 10.8 Hz), 4.05 (s, 2H), 3.99–3.42 (m, 16H), 2.73 (dd, 1H, *J* = 4.8 and 12.6 Hz), 2.07 (s, 3H), 1.90 (m, 2H), 1.69 (t, 1H, *J* = 12.6 Hz); ¹³C NMR (75 MHz, D₂O) δ 174.67, 173.55, 171.31, 100.51, 97.22, 72.37, 71.97, 69.64, 68.66, 68.34, 68.22, 67.63, 65.30, 64.01, 62.75, 52.07, 52.05, 50.09, 48.31, 40.44, 28.07, 21.10. HRMS (ESI) *m/z* calcd for C₂₂H₃₇N₈O₁₄ (M+H) 637.2429, found 637.2425.

3-Azidopropyl *O*-(5-fluoroacetamido-3,5-dideoxy-D-glycero- α -D-galacto-2-nonulopyranosylonic acid)-(2 \rightarrow 6)-2-acetamido-2-deoxy- α -D-galactopyranoside (20, Neu5AcF α 2–6GalNAc α ProN₃). 74 mg, Yield, 80%; white foam. [α]_D²³ = +53.7° (*c* 1.0, H₂O); v_{max}/cm⁻¹ 3292 (s, OH), 2933 (s, C–H, alkene), 2100 (s, N₃), 1606 (s, C=O, carboxylic acid), 1560 (m, C=O, amide), 1028 (s, C-N); ¹H NMR (600 MHz, D₂O) δ 4.87(d, 1H, *J* = 3.6 Hz), 4.13 (dd, 1H, *J* = 3.6 and 11.4 Hz), 4.03 (m, 1H), 3.96–3.42 (m, 15H), 2.74 (dd, 1H, *J* = 4.8 and 12.6 Hz), 2.03 (s, 3H), 1.90 (m, 2H), 1.69 (t, 1H, *J* = 12.6 Hz), 4.95 (s, 1H), 4.88 (s, 1H) ; ¹³C NMR (75 MHz, D₂O) δ 174.68, 173.54, 171.66, 100.53, 97.22, 79.97, 72.30, 72.02, 69.65, 68.69, 68.25, 68.22, 67.64, 65.31, 64.03, 62.77, 51.61, 50.10, 48.32, 40.43, 28.07, 22.10. HRMS (ESI) *m*/*z* calcd for C₂₂H₃₇FN₅O₁₄ (M+H) 614.2321, found 614.2313.

3-Azidopropyl 0-(5-phenylmethoxyacetamido-3,5-dideoxy-D-glycero- α -D-galacto-2-acid)-(2 \rightarrow 6)-2-acetamido-2-deoxy- α -D-galactopyranoside (21, Neu5GcBn α 2–6GalNAc α ProN₃). 77 mg, Yield, 72%; white foam. [α]_D²³ = +50.8° (*c* 1.0, H₂O); v_{max} /cm⁻¹ 3301 (s, OH), 2932 (s, C–H, alkene), 2096 (s, N₃), 1611 (s, C=O, carboxylic acid), 1542 (m, C=O, amide), 1032 (s, C-N); ¹H NMR (600 MHz, D₂O) δ 7.47–7.42 (m, 5H) 4.87 (d, 1H, *J* = 3.6 Hz), 4.66 (s, 2H), 4.15 (dd, *J* = 3.6, 10.8), 4.11 (s, 2H), 4.05–3.41 (m, 16H), 2.73 (dd, *J* = 4.8 and 12.6 Hz), 2.04 (s, 3H), 1.89 (m, 2H), 1.69 (t, 1H, *J* = 12.0 Hz); ¹³C NMR (75 MHz, D₂O) δ 174.66, 173.54, 171.67, 136.71, 128.99, 128.80, 128.77, 100.51, 97.22, 73.49, 72.43, 72.00, 69.64, 68.57, 68.43, 68.11, 67.64, 65.30, 64.00, 62.79, 51.74, 50.09, 48.31, 40.53, 28.07, 22.10. HRMS (ESI) *m/z* calcd for C₂₉H₄₄N₅O₁₅ (M+H) 702.2834, found 702.2836.

3-Azidopropyl *O*-[5-(N-benzyloxycarboxyamido)glycylamido-3,5-dideoxy-*D*-glycero- α -*D*-galacto-2-nonulopyranosylonic acid]-(2 \rightarrow 6)-2-acetamido-2-deoxy- α -*D*-galactopyranoside (22, Neu5GlyCbz α 2–6LacProN₃). 75 mg, Yield, 67%; white foam. [α]_D²⁴ = +50.7° (*c* 1.0, H₂O); v_{max} /cm⁻¹ 3286 (s, OH), 2942 (s, C–H, alkene), 2103 (s, N₃), 1616 (s, C=O, carboxylic acid), 1542 (m, C=O, amide), 1032 (s, C-N); ¹H NMR (600 MHz, D₂O) δ 7.45–7.39 (m, 5H), 5.12 (m, 2H), 4.85 (d, 1H, *J* = 3.6 Hz), 4.12(dd, *J* = 3.6 and 11.4 Hz), 4.06–3.40 (m, 18H), 2.71 (dd, 1H, 4.8, 12.6), 2.05 (s, 3H), 1.87 (m, 2H), 1.66 (t, 1H, *J* = 12.6 Hz); ¹³C NMR (75 MHz, D₂O) δ 177.23, 176.10, 175.78, 161.22, 138.93, 131.52, 131.18, 130.49, 103.07, 99.78, 75.06, 74.58, 72.19, 71.23, 70.91, 70.74, 70.20, 70.06, 67.86, 66.53, 65.39, 54.63, 52.65, 50.88, 46.42, 42.96, 30.63, 24.66. HRMS (ESI) *m*/z calcd for C₃₀H₄₅N₆O₁₆ (M+H) 745.2892, found 745.2892.

dioxobutyl]amino]-Benzoic acid (23, Neu5Aca2–6GalNAca2AA). 41 mg, Yield, 64%; white foam. $[\alpha]_D^{24} = +50.2^{\circ}$ (*c* 1.0, H₂O); ν_{max} /cm⁻¹ 3282 (s, OH), 2927 (s, C–H, alkene), 1607 (s, C=O, carboxylic acid), 1529 (m, C=O, amide), 1031 (s, C-N); ¹H NMR (600 MHz, D₂O) δ 7.94–7.27 (m,

4H), 4.79 (d, 1H, J = 3.6 Hz), 4.05 (dd, 1H, J = 3.6 and 10.8 Hz), 3.84 (s, 3H), 3.91–3.53 (m, H), 3.37 (m, 1H), 3.25 (m, 2H), 2.73 (t, 2H, J = 6.6 Hz), 2.69 (dd, 1H, J = 4.8 and 12.6 Hz), 2.60 (t, 2H, J = 6.6 Hz), 1.99 (s, 3H), 1.97 (s, 3H), 1.75 (m, 2H), 1.63 (t, 1H, J = 12.0 Hz). ¹³C NMR (75 MHz, D₂O) δ 175.16, 174.60, 174.56, 173.56, 173.50, 169.26, 137.27, 134.16, 131.02, 125.39, 123.45, 120.90, 100.47, 97.04, 72.70, 71.90, 69.56, 68.66, 68.39, 67.81, 65.15, 63.93, 62.76, 52.93, 52.01, 49.99, 40.44, 36.28, 32.61, 31.18, 28.14, 22.17, 22.06. HRMS (ESI) *m*/*z* calcd for C₃₄H₅₁N₄O₁₈ (M+H) 803.3198, found 803.3202.

N-9-Fluorenylmethoxycarbonyl *O*-(5-acetamido-3,5-dideoxy-D-glycero-α-D-galacto-2nonulopyranosylonic acid)-(2→6)-2-acetamido-2-deoxy-α-D-galactopyranosyl-L-Serine (24, Neu5Acα2–6GalNAcαSer). 61 mg, Yield, 72%; white foam. $[α]_D^{24} = +42.5^\circ$ (*c* 0.75, H₂O); v_{max} /cm⁻¹ 3309 (s, OH), 2942 (s, C–H, alkene), 1603 (s, C=O, carboxylic acid), 1558 (m, C=O, amide), 1033 (s, C-N); ¹H NMR (600 MHz, D₂O): δ 7.89–7.41 (m, 8H), 4.82 (d, 1H, *J* = 3.6 Hz), 4.67–4.57 (m, 2H), 4.30–3.49 (m, 17H), 2.70 (dd, 1H, *J* = 4.8 and 12.0 Hz), 2.02 (s, 3H), 1.59 (t, 1H, *J* = 12.0 Hz). ¹³C NMR (150 MHz, D₂O): δ 175.16, 174.85, 174.69, 173.47, 157.59, 144.11, 143.98, 141.12, 128.19, 127.72, 125.14, 125.06, 120.32, 100.49, 97.76, 72.68, 71.87, 69.67, 68.58, 68.51, 68.44, 68.42, 67.60, 66.33, 63.61, 62.74, 61.86, 52.00, 49.82, 47.09, 40.43, 22.17, 20.65. HRMS (ESI) m/z calcd for C₃₇H₄₈N₃O₁₈ (M+H) 822.2933, found 822.2936.

N-9-Fluorenylmethoxycarbonyl *O*-(5-acetamido-3,5-dideoxy-D-glycero-α-D-galacto-2-nonulopyranosylonic acid)-(2→6)-2-acetamido-2-deoxy-α-D-galactopyranosyl- L-Threonine (25, Neu5Acα2–6GalNAcαThr). 40 mg, Yield, 51%; white foam. $[\alpha]_D^{24} = +41.2^{\circ}$ (*c* 0.75, H₂O); v_{max}/cm^{-1} 3301 (s, OH), 2932 (s, C–H, alkene), 1600 (s, C=O, carboxylic acid), 1560 (m, C=O, amide), 1032 (s, C-N); ¹H NMR (600 MHz, D₂O): δ 7.90–7.41 (m, 8H), 4.94 (d, 1H, *J* = 3.6 Hz), 4.61 (dd, 1H, *J* = 3.0 and 12.0 Hz), 4.30–3.52 (m, 13H), 2.79 (dd, 1H, *J* = 4.8 and 12.6 Hz), 2.03 (s, 3H), 1.93 (s, 3H), 1.70 (t, 1H, *J* = 12.0 Hz), 0.94 (d, 3H, *J* = 6.0 Hz). ¹³C NMR (100 MHz, D₂O): δ 175.20, 174.79, 174.74, 174.61, 173.48, 158.16, 144.24, 143.73, 141.30, 141.19, 128.35, 128.19, 127.76, 127.72, 125.15, 124.92, 120.25, 100.48, 99.14, 78.08, 72.70, 71.92, 69.81, 68.67, 68.45, 68.42, 67.86, 65.64, 63.74, 62.72, 52.07, 50.02, 47.62, 40.38, 22.34, 22.18, 18.31. HRMS (ESI) m/z calcd for C₃₈H₅₀N₃O₁₈ (M+H) 836.3089, found 836.3094.

References

- 1. M. Sun, Y. Li, H. A. Chokhawala, R. Henning and X. Chen, Biotechnol. Lett., 2008, 30, 671–676.
- 2. H. Yu, H. Chokhawala, R. Karpel, H. Yu, B. Wu, J. Zhang, Y. Zhang, Q. Jia and X. Chen, J. Am. Chem. Soc., 2005, 127, 17618–17619.
- 3. H. Yu, S. Huang, H. Chokhawala, M. Sun, H. Zheng and X. Chen, Angew. Chem. Int. Ed. Engl., 2006, 45, 3938–3944.
- 4. H. Cao, Y. Li, K. Lau, S. Muthana, H. Yu, J. Cheng, H. A. Chokhawala, G. Sugiarto, L. Zhang and X. Chen, *Org. Biomol. Chem.*, 2009, 7, 5137–5145.
- 5. H. Yu, V. Thon, K. Lau, L. Cai, Y. Chen, S. Mu, Y. Li, P. G. Wang and X. Chen, *Chem. Commun.* (*Camb.*), 2010, **46**, 7507–7509.















¹H & ¹³C NMR of Neu5GcBn α 2–6GalNAc α ProN₃ 21

 ^{1}H & ^{13}C NMR of Neu5AcCbz\alpha2–6GalNAcaProN3 **22**

Electronic Supplementary Material (ESI) for Chemical Communications This journal is The Royal Society of Chemistry 2011

